搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Burkholderia cepacia 5-methyltetrahydropteroyltriglutamate--homocysteine methyltransferase (metE), partial CSB-YP457580BXS
CSB-EP457580BXS
CSB-BP457580BXS
CSB-MP457580BXS
CSB-EP457580BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bungarus multicinctus Protease inhibitor-like protein 2 CSB-YP457581BXN
CSB-EP457581BXN
CSB-BP457581BXN
CSB-MP457581BXN
CSB-EP457581BXN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase (gpmA) CSB-YP457582EYZ
CSB-EP457582EYZ
CSB-BP457582EYZ
CSB-MP457582EYZ
CSB-EP457582EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Deoxycytidine triphosphate deaminase (dcd) CSB-YP457583EYZ
CSB-EP457583EYZ
CSB-BP457583EYZ
CSB-MP457583EYZ
CSB-EP457583EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Heat shock protein hspQ (hspQ) CSB-YP457584EYZ
CSB-EP457584EYZ
CSB-BP457584EYZ
CSB-MP457584EYZ
CSB-EP457584EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis 50S ribosomal protein L32 (rpmF) CSB-YP457585EYZ
CSB-EP457585EYZ
CSB-BP457585EYZ
CSB-MP457585EYZ
CSB-EP457585EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis UDP-4-amino-4-deoxy-L-arabinose--oxoglutarate aminotransferase (arnB) CSB-YP457586EYZ
CSB-EP457586EYZ
CSB-BP457586EYZ
CSB-MP457586EYZ
CSB-EP457586EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Multidrug resistance protein MdtH (mdtH), partial CSB-YP457587EYZ
CSB-EP457587EYZ
CSB-BP457587EYZ
CSB-MP457587EYZ
CSB-EP457587EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis tRNA (cmo5U34)-methyltransferase CSB-YP457588EYZ
CSB-EP457588EYZ
CSB-BP457588EYZ
CSB-MP457588EYZ
CSB-EP457588EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis 6,7-dimethyl-8-ribityllumazine synthase (ribH) CSB-YP457589EYZ
CSB-EP457589EYZ
CSB-BP457589EYZ
CSB-MP457589EYZ
CSB-EP457589EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis UPF0133 protein PMI0140 (PMI0140) CSB-YP457590EYZ
CSB-EP457590EYZ
CSB-BP457590EYZ
CSB-MP457590EYZ
CSB-EP457590EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis 23S rRNA (uracil (1939)-C (5))-methyltransferase RlmD CSB-YP457591EYZ
CSB-EP457591EYZ
CSB-BP457591EYZ
CSB-MP457591EYZ
CSB-EP457591EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Probable Fe (2+)-trafficking protein CSB-YP457592EYZ
CSB-EP457592EYZ
CSB-BP457592EYZ
CSB-MP457592EYZ
CSB-EP457592EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Na (+)-translocating NADH-quinone reductase subunit E, partial CSB-YP457593EYZ1
CSB-EP457593EYZ1
CSB-BP457593EYZ1
CSB-MP457593EYZ1
CSB-EP457593EYZ1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Protein CrcB homolog (crcB), partial CSB-YP457594EYZ1
CSB-EP457594EYZ1
CSB-BP457594EYZ1
CSB-MP457594EYZ1
CSB-EP457594EYZ1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Leucine--tRNA ligase (leuS), partial CSB-YP457595EYZ
CSB-EP457595EYZ
CSB-BP457595EYZ
CSB-MP457595EYZ
CSB-EP457595EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Serine--tRNA ligase (serS) CSB-YP457596EYZ
CSB-EP457596EYZ
CSB-BP457596EYZ
CSB-MP457596EYZ
CSB-EP457596EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Probable phosphatase PMI1003 (PMI1003) CSB-YP457597EYZ
CSB-EP457597EYZ
CSB-BP457597EYZ
CSB-MP457597EYZ
CSB-EP457597EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Electron transport complex protein RnfA (rnfA), partial CSB-YP457598EYZ1
CSB-EP457598EYZ1
CSB-BP457598EYZ1
CSB-MP457598EYZ1
CSB-EP457598EYZ1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Multifunctional CCA protein (cca) CSB-YP457599EYZ
CSB-EP457599EYZ
CSB-BP457599EYZ
CSB-MP457599EYZ
CSB-EP457599EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開(kāi)發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開(kāi)發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見(jiàn)問(wèn)題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問(wèn),涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>